Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury

American Journal of Nephrology

Volumn 28, Issue 2, 2008, Pages 203-209

  Kolyada, Alexey Y ^a   Liangos, Orfeas ^a   Madias, Nicolaos E ^a   Jaber, Bertrand L ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Erythropoietin; Radiocontrast medium; Renal tubular epithelial cells

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; IODIXANOL; IOHEXOL; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL VIABILITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VITRO STUDY; KIDNEY TUBULE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTECTION;

ANIMALS; APOPTOSIS; CASPASES; CELL SURVIVAL; CONTRAST MEDIA; ENZYME ACTIVATION; EPITHELIAL CELLS; ERYTHROPOIETIN, RECOMBINANT; IN SITU NICK-END LABELING; IOHEXOL; KIDNEY TUBULES; LLC-PK1 CELLS; REPERFUSION INJURY; SWINE; TRIIODOBENZOIC ACIDS;

EID: 38349007041     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110089     Document Type: Article

References (39)

1. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489-1494.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
3. Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
4. Mehran R, Aymong ED, Nikolsky E, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
5. Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;100:S11-S15.
6. Zager RA, Johnson AC, Hanson SY: Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int 2003;64:128-139.
7. Itoh Y, Yano T, Sendo T, Oishi R: Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci 2005;97:473-488.
8. Barrett BJ, Parfrey PS: Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379-386.
9. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
10. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334.
11. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43:1-9.
12. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
13. Porter AG, Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99-104.
14. Yang B, El Nahas AM, Thomas GL, et al: Caspase-3 and apoptosis in experimental chronic renal scarring. Kidney Int 2001;60:1765-1776.
15. Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL: C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. Eur J Clin Invest 2004;34:50-56.
16. Yano T, Itoh Y, Sendo T, Kubota T, Oishi R: Cyclic AMP reverses radiocontrast mediainduced apoptosis in LLC-PK1 cells by activating A kinase/PI 3 kinase. Kidney Int 2003;64:2052-2063.
17. Yano T, Itoh Y, Kubota T, Sendo T, Oishi R: A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLCPK1 cells injury. Kidney Int 2004;65:1654-1663.
18. Yano T, Itoh Y, Kubota T, et al: A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol 2005;166:1333-1342.
19. 2 and myoglobin-induced proximal tubular cell attack. Kidney Int 1998;53:1661-1672.
20. Lorusso V, Taroni P, Alvino S, Spinazzi A: Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol 2001;36:309-316.
21. Donnelly PK, Burwell N, McBurney A, Ward JW, Walls J, Watkin EM: Hemodialysis and iopamidol clearance after subclavian venography. Invest Radiol 1993;28:629-632.
22. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
23. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-163.
24. Adamson JW, Eschbach JW: Erythropoietin for end-stage renal disease. N Engl J Med 1998;339:625-627.
25. Peterson TE, Katusic ZS: EPO tecting the endothelium. Br J Pharmacol 2007;150:823-825.
26. Boogaerts M: Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr Med Res Opin 2006;22(suppl 4):15-22.
27. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-381.
28. Bittorf T, Seiler J, Ludtke B, Buchse T, Jaster R, Brock J: Activation of STAT5 during EPO-directed suppression of apoptosis. Cell Signal 2000;12:23-30.
29. Bittorf T, Jaster R, Brock J: Rapid activation of the MAP kinase pathway in hematopoietic cells by erythropoietin, granulocytemacrophage colony-stimulating factor and interleukin-3. Cell Signal 1994;6: 305-311.
30. Haseyama Y, Sawada K, Oda A, et al: Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood 1999;94: 1568-1577.
31. Renzi MJ, Farrell FX, Bittner A, et al: Erythropoietin induces changes in gene expression in PC-12 cells. Brain Res Mol Brain Res 2002;104: 86-95.
32. Vairano M, Dello Russo C, Pozzoli G, et al: Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci 2002;16:584-592.
33. Wen TC, Sadamoto Y, Tanaka J, et al: Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by upregulating Bcl-xL expression. J Neurosci Res 2002;67:795-803.
34. Sharples EJ, Patel N, Brown P, et al: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
35. Buemi M, Vaccaro M, Sturiale A, et al: Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps. Acta Derm Venereol 2002;82:411-417.
36. Bagnis C, Beaufils H, Jacquiaud C, et al: Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-938.
37. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004;19:348-355.
38. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806-1813.
39. Brines M, Cerami A: Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-250.